AVITA Medical, Inc. Australian S.E.

Equities

AVH

AU000000AVH4

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
2.62 ^AUD	-5.42%		-6.43%	-38.93%

Apr. 17	Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03	MT
Apr. 11	BTIG Research Downgrades Avita Medical to Neutral From Buy	MT

Avita Medical : Appendix 4A

August 05, 2020 at 04:22 am EDT

ab3ccd4b-c3aa-4158-ac14-f1a54ff5dad4.pdf138.5 KB

Attachments

Original document
Permalink

Disclaimer

Avita Therapeutics Inc. published this content on 05 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2020 08:21:09 UTC

Latest news about AVITA Medical, Inc.

Wilsons Downgrades Avita Medical to Market-Weight From Overweight; Price Target is AU$3.03	Apr. 17	MT
BTIG Research Downgrades Avita Medical to Neutral From Buy	Apr. 11	MT
Avita Medical Lowers Q1 Revenue Guidance on Slower New Account Approvals	Apr. 10	MT
AVITA Medical, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2024 and Full Year Fiscal 2024	Apr. 10	CI
AVITA Medical, Inc.(ASX:AVH) added to S&P/ASX All Ordinaries Index	Mar. 17	CI
AVITA Medical, Inc.(NasdaqCM:RCEL) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
AVITA Medical Submits Additional RECELL GO PMA Supplement Information to US FDA	Feb. 29	MT
Transcript : AVITA Medical, Inc. - Special Call	Feb. 27
Piper Sandler Raises Price Target on Avita Medical to $21 From $19, Maintains Overweight Rating	Feb. 26	MT
Transcript : AVITA Medical, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
AVITA Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
AVITA Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Feb. 22	CI
Cantor Fitzgerald Adjusts Price Target on Avita Medical to $22 From $20, Maintains Overweight Rating	Jan. 19	MT
Transcript : AVITA Medical, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	Jan. 11
Sector Update: Health Care Stocks Softer Thursday Afternoon	Jan. 11	MT
Sector Update: Health Care Stocks Mixed Premarket Thursday	Jan. 11	MT
Sector Update: Health Care	Jan. 11	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday on Expected Rate Cut Trajectory Insights	Jan. 11	MT
Avita Medical Signs US Distribution Agreement for Wound Healing Products	Jan. 11	MT
Avita Medical Signs Deal with Stedical Scientific for US Distribution of PermeaDerm	Jan. 10	MT
AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific	Jan. 10	CI
Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024	Jan. 10	CI
Transcript : AVITA Medical, Inc. - Special Call	Dec. 05
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Nov. 21	MT

Chart AVITA Medical, Inc.

Duration

Period

More charts

Company Profile

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for AVITA Medical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.76 AUD

Average target price

40.65 AUD

Spread / Average Target

+218.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+2.19%	42.59B
MODERNA, INC.	+7.47%	40.65B
LONZA GROUP AG	+49.05%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+9.05%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.37%	18.17B
MEDPACE HOLDINGS, INC.	+28.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.78%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.09%	11.1B

Other Biotechnology & Medical Research